77 research outputs found
Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth
A role for Hedgehog (Hh) signalling in the development of colorectal cancer
(CRC) has been proposed. In CRC and other solid tumours, Hh ligands are
upregulated; however, a specific Hh antagonist provided no benefit in a
clinical trial. Here we use Hh reporter mice to show that downstream Hh
activity is unexpectedly diminished in a mouse model of colitis-associated
colon cancer, and that downstream Hh signalling is restricted to the stroma.
Functionally, stroma-specific Hh activation in mice markedly reduces the
tumour load and blocks progression of advanced neoplasms, partly via the
modulation of BMP signalling and restriction of the colonic stem cell
signature. By contrast, attenuated Hh signalling accelerates colonic
tumourigenesis. In human CRC, downstream Hh activity is similarly reduced and
canonical Hh signalling remains predominantly paracrine. Our results suggest
that diminished downstream Hh signalling enhances CRC development, and that
stromal Hh activation can act as a colonic tumour suppressor
Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer
Cellular mechanisms in basic and clinical gastroenterology and hepatolog
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
The aim of this study was to elucidate the prognostic impact of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and aldehyde dehydrogenase-1 (ALDH1) in colorectal cancer
Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells
BACKGROUND: Prostate cancer cells communicate reciprocally with the stromal cells surrounding them, inside the prostate, and after metastasis, within the bone. Each tissue secretes factors for interpretation by the other. One stromally-derived factor, Hepatocyte Growth Factor (HGF), was found twenty years ago to regulate invasion and growth of carcinoma cells. Working with the LNCaP prostate cancer progression model, we found that these cells could respond to HGF stimulation, even in the absence of Met, the only known HGF receptor. The new HGF binding partner we find on the cell surface may help to clarify conflicts in the past literature about Met expression and HGF response in cancer cells. METHODS: We searched for Met or any HGF binding partner on the cells of the PC3 and LNCaP prostate cancer cell models, using HGF immobilized on agarose beads. By using mass spectrometry analyses and sequencing we have identified nucleolin protein as a novel HGF binding partner. Antibodies against nucleolin (or HGF) were able to ameliorate the stimulatory effects of HGF on met-negative prostate cancer cells. Western blots, RT-PCR, and immunohistochemistry were used to assess nucleolin levels during prostate cancer progression in both LNCaP and PC3 models. RESULTS: We have identified HGF as a major signaling component of prostate stromal-conditioned media (SCM) and have implicated the protein nucleolin in HGF signal reception by the LNCaP model prostate cancer cells. Antibodies that silence either HGF (in SCM) or nucleolin (on the cell surfaces) eliminate the adhesion-stimulatory effects of the SCM. Likewise, addition of purified HGF to control media mimics the action of SCM. C4-2, an LNCaP lineage-derived, androgen-independent human prostate cancer cell line, responds to HGF in a concentration-dependent manner by increasing its adhesion and reducing its migration on laminin substratum. These HGF effects are not due to shifts in the expression levels of laminin-binding integrins, nor can they be linked to expression of the known HGF receptor Met, as neither LNCaP nor clonally-derived C4-2 sub-line contain any detectable Met protein. Even in the absence of Met, small GTPases are activated, linking HGF stimulation to membrane protrusion and integrin activation. Membrane-localized nucelolin levels increase during cancer progression, as modeled by both the PC3 and LNCaP prostate cancer progression cell lines. CONCLUSION: We propose that cell surface localized nucleolin protein may function in these cells as a novel HGF receptor. Membrane localized nucleolin binds heparin-bound growth factors (including HGF) and appears upregulated during prostate cancer progression. Antibodies against nucleolin are able to ameliorate the stimulatory effects of HGF on met-negative prostate cancer cells. HGF-nucleolin interactions could be partially responsible for the complexity of HGF responses and met expression reported in the literature
Comprehensive Profiling of N‑Linked Glycosylation Sites in HeLa Cells Using Hydrazide Enrichment
The adenocarcinoma cell line HeLa serves as a model
system for cancer research in general and cervical cancer in particular. In
this study, hydrazide enrichment in combination with state-of-the art
nanoLC−MS/MS analysis was used to profile N-linked glycosites in HeLa
cells. N-Linked glycoproteins were selectively enriched in HeLa cells by
the hydrazide capture method, which isolates all glycoproteins
independent of their glycans. Nonglycosylated proteins were removed
by extensive washing. N-Linked glycoproteins were identified with the
specific NXT/S motif and deamidated asparagine (N). Deglycosylation
was carried out in both H_2 (^16)O and H_2 ^(18)O to confirm the deamidation.
NanoLC−MS/MS analysis indicated that the method selectively enriched
at least 100 fold N-linked glycosites in HeLa cells. When both the
membrane and cytosolic fractions were used, a total of 268 unique N-glycosylation
sites were identified corresponding to 106 glycoproteins.
Bioinformatic analysis revealed that most of the glycoproteins identified
are known to have an impact on cancer and have been proposed as
biomarkers
Rwanda – lasting imprints of a genocide: trauma, mental health and psychosocial conditions in survivors, former prisoners and their children
DNA copy number aberrations in breast cancer by array comparative genomic hybridization
Array comparative genomic hybridization (CGH) has been popularly used for analyzing DNA copy number variations in diseases like cancer. In this study, we investigated 82 sporadic samples from 49 breast cancer patients using 1-Mb resolution bacterial artificial chromosome CGH arrays. A number of highly frequent genomic aberrations were discovered, which may act as “drivers” of tumor progression. Meanwhile, the genomic profiles of four “normal” breast tissue samples taken at least 2cm away from the primary tumor sites were also found to have some genomic aberrations that recurred with high frequency in the primary tumors, which may have important implications for clinical therapy. Additionally, we performed class comparison and class prediction for various clinicopathological parameters, and a list of characteristic genomic aberrations associated with different clinicopathological phenotypes was compiled. Our study provides clues for further investigations of the underlying mechanisms of breast carcinogenesis
Expression of CD44 splice variants during lymphocyte activation and tumor progression
Recently, splice variants of CD44 have been described that confer metastatic potential to non-metastasizing rat pancreatic carcinoma and sarcoma cell lines. Using antibodies against variant CD44 (CD44v) sequences, we have examined the expression of variant CD44 glycoproteins on human lymphoid cells and tissues and in colorectal neoplasia. Lymphohematopoietic cells express low levels of CD44v glycoproteins. During the process of lymphocyte activation in vitro and in vivo, expression of CD44v glycoproteins is transiently upregulated. The reaction pattern of various antibodies indicates that these CD44 variants contain the domain encoded by exon v6, which is part of the variant that confers metastatic capability. In human colorectal neoplasia we observed overexpression of CD44 splice variants in all invasive carcinomas. Already at early stages of colorectal tumor progression exon v5 epitopes were overexpressed. Tumor progression was strongly related to expression of CD44 isoforms containing exon v6 encoded domains. The findings establish CD44 variants as tumor progression markers in colorectal cance
- …